Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) is a highly malignant urologic cancer and tends to metastasize. Although immune checkpoint inhibitors (ICIs) bring a glimmer of light to conquer ACC, only a fraction of patients have benefit from ICIs treatment. It is well known that tumor mutational burden...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Fangshi, Guan, Yibing, Zhang, Peng, Xue, Li, Ma, Yubo, Gao, Mei, Chong, Tie, Ren, Bin-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107278/
https://www.ncbi.nlm.nih.gov/pubmed/35568842
http://dx.doi.org/10.1186/s12902-022-01017-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107278/
https://www.ncbi.nlm.nih.gov/pubmed/35568842
http://dx.doi.org/10.1186/s12902-022-01017-3

Ejemplares similares